Treatment of glioblastoma with intravenous taurolidine. First clinical experience.
Treatment of glioblastoma with intravenous taurolidine. First clinical experience.
复制标题
DOI：
--
复制
发表时间：
2004-03
影响因子：
2
通讯作者：
R. Stendel;T. Picht;A. Schilling;J. Heidenreich;C. Loddenkemper;W. Jänisch;M. Brock
中科院分区：
文献类型：
--
作者：
R. Stendel;T. Picht;A. Schilling;J. Heidenreich;C. Loddenkemper;W. Jänisch;M. Brock
尽管诊断和治疗取得了进展，但胶质母细胞瘤患者的预后仍然很差。最近发现，抗菌剂牛磺罗定通过诱导程序性细胞死亡对脑肿瘤细胞具有直接和选择性的抑制作用。本文报道了两例常规治疗无效的进展性胶质母细胞瘤患者静脉注射牛磺罗定治疗。患者和方法两名组织病理学诊断为胶质母细胞瘤的男性患者纳入研究。尽管常规治疗，肿瘤仍在进行。开始静脉内牛磺罗定治疗。结果两例患者的神经系统状况和生活质量均得到改善，可以出院继续门诊治疗。随访显示两名患者的肿瘤部分缓解。然而，两名患者在开始牛磺罗定治疗后约4个月分别死于肺炎和急性血栓栓塞。结论两例患者的生活质量均得到短暂的显著改善，肿瘤部分缓解。对牛磺罗定治疗有明显反应。
BACKGROUND Despite progress in diagnosis and therapy, the prognosis of patients with glioblastoma remains poor. Recently it has been found that the antibacterial agent taurolidine has a direct and selective antineoplastic effect on brain tumor cells by the induction of programmed cell death. This paper reports on intravenous taurolidine treatment in two patients with a progressive glioblastoma despite conventional therapy. PATIENTS AND METHODS Two male patients with histopathologically diagnosed glioblastoma were included. The tumors were progressive despite conventional therapy. Intravenous taurolidine treatment was initiated. RESULTS The neurological condition and quality of life improved in both patients such that they could be discharged for further outpatient treatment. Follow-up demonstrated partial remission of the tumor in both patients. However, both patients died about 4 months following the start of taurolidine treatment, from pneumonia and acute thrombembolism, respectively. CONCLUSION Both patients achieved a transient, marked improvement in quality of life and partial tumor remission. There was a clear response to the taurolidine treatment.